# Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

> **NCT04830462** · PHASE4 · COMPLETED · sponsor: **Herlev and Gentofte Hospital** · enrollment: 32 (actual)

## Conditions studied

- Latent Tuberculosis
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Rifampicin 300 Mg Oral Capsule
- **DRUG:** Isoniazid 300 Mg ORAL TABLET

## Key facts

- **NCT ID:** NCT04830462
- **Lead sponsor:** Herlev and Gentofte Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-15
- **Primary completion:** 2023-05-01
- **Final completion:** 2023-05-01
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04830462

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04830462, "Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04830462. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*